NCT05247528 - Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions

Resistant HypertensionDifficult to Control Hypertension

Interventions

DRUG

MANP

Novel designer peptide to represent a pGC-A/cGMP therapeutic

DRUG

Placebo

Placebo Comparator

Trial Locations (5)

USA Clinical Site 04, Decatur

USA Clinical Site 02, DeLand

USA Clinical Site 03, Anniston

USA Clinical Site 05, Owensboro

USA Clinical Site 01, Tustin